Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Bebtelovimab (Alias: LY-COV1404, LY-3853113)

Catalog No. T78252 Copy Product Info
🥰Excellent
Bebtelovimab (LY-CoV1404) is a neutralizing, fully human IgG1 monoclonal antibody targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This product binds specifically to a highly conserved epitope on the RBD, blocking the interaction between the spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Bebtelovimab exhibits potent and broad neutralizing activity against various SARS-CoV-2 variants, including Omicron (BA.1/BA.2), Delta, and other earlier strains. In clinical settings, it is utilized to reduce the risk of severe disease progression in high-risk ambulatory patients, such as solid organ transplant recipients.

Bebtelovimab

Copy Product Info
🥰Excellent
Catalog No. T78252
Alias LY-COV1404, LY-3853113

Bebtelovimab (LY-CoV1404) is a neutralizing, fully human IgG1 monoclonal antibody targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This product binds specifically to a highly conserved epitope on the RBD, blocking the interaction between the spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Bebtelovimab exhibits potent and broad neutralizing activity against various SARS-CoV-2 variants, including Omicron (BA.1/BA.2), Delta, and other earlier strains. In clinical settings, it is utilized to reduce the risk of severe disease progression in high-risk ambulatory patients, such as solid organ transplant recipients.

Bebtelovimab
Cas No. 2578319-11-4
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$2472-4 weeks2-4 weeks
5 mg$6472-4 weeks2-4 weeks
10 mg$9872-4 weeks2-4 weeks
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Bebtelovimab (LY-CoV1404) is a neutralizing, fully human IgG1 monoclonal antibody targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This product binds specifically to a highly conserved epitope on the RBD, blocking the interaction between the spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Bebtelovimab exhibits potent and broad neutralizing activity against various SARS-CoV-2 variants, including Omicron (BA.1/BA.2), Delta, and other earlier strains. In clinical settings, it is utilized to reduce the risk of severe disease progression in high-risk ambulatory patients, such as solid organ transplant recipients.
In vitro
In biochemical assays, Bebtelovimab binds to a conserved epitope on the SARS-CoV-2 RBD with high affinity. It effectively neutralizes the original strain and multiple variants of concern (including Delta and Omicron) by preventing the binding of the viral spike protein to the host ACE2 receptor [2].
SynonymsLY-COV1404, LY-3853113
Reactivity
Virus
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetSARS-CoV-2
Chemical Properties
Cas No.2578319-11-4
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Bebtelovimab | purchase Bebtelovimab | Bebtelovimab cost | order Bebtelovimab | Bebtelovimab in vitro